

# Steven Skates

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11562353/publications.pdf>

Version: 2024-02-01

15  
papers

1,438  
citations

932766

10  
h-index

996533

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

1912  
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. <i>Gynecologic Oncology</i> , 2008, 108, 402-408.	0.6	594
2	Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1458-1464.	3.0	268
3	Development of a Multimarker Assay for Early Detection of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2159-2166.	0.8	246
4	Prevention and Early Detection of Ovarian Cancer: Mission Impossible?. <i>Recent Results in Cancer Research</i> , 2007, 174, 91-100.	1.8	92
5	Differential Diagnosis of a Pelvic Mass. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S5-S8.	1.2	63
6	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. <i>Clinical Cancer Research</i> , 2015, 21, 4960-4969.	3.2	62
7	Protein Z: A putative novel biomarker for early detection of ovarian cancer. <i>International Journal of Cancer</i> , 2016, 138, 2984-2992.	2.3	41
8	Molecular Markers for Early Detection of Renal Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6296S-6301S.	3.2	25
9	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 391-400.	0.7	17
10	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz075.	1.4	11
11	Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 257.e1-257.e6.	0.7	7
12	Urokinase-Type Plasminogen Activator Receptor: A Beacon of Malignancy?. <i>Clinical Cancer Research</i> , 2008, 14, 5643-5645.	3.2	6
13	Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. <i>Tumor Biology</i> , 2021, 43, 355-365.	0.8	4
14	Validation of a multi-marker panel for early detection of ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5570-5570.	0.8	1
15	Extracellular vesicle-based biomarker assay for the detection of early-stage ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5542-5542.	0.8	1